Arrieta Arcelia, Battelino Tadej, Scaramuzza Andrea E, Da Silva Julien, Castañeda Javier, Cordero Toni L, Shin John, Cohen Ohad
Medtronic Bakken Research Center, Maastricht, The Netherlands.
University Children's Hospital, University Medical Centre Ljubljana and Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.
Diabetes Obes Metab. 2022 Jul;24(7):1370-1379. doi: 10.1111/dom.14714. Epub 2022 May 12.
To investigate real-world glycaemic outcomes and goals achieved by users of the MiniMed 780G advanced hybrid closed loop (AHCL) system aged younger and older than 15 years with type 1 diabetes (T1D).
Data uploaded by MiniMed 780G system users from 27 August 2020 to 22 July 2021 were aggregated and retrospectively analysed based on self-reported age (≤15 years and >15 years) for three cohorts: (a) post-AHCL initiation, (b) 6-month longitudinal post-AHCL initiation and (c) pre- versus post-AHCL initiation. Analyses included mean percentage of time spent in AHCL and at sensor glucose ranges, insulin delivered and the proportion of users achieving recommended glucose management indicator (GMI < 7.0%) and time in target range (TIR 70-180 mg/dl > 70%) goals.
Users aged 15 years or younger (N = 3211) achieved a GMI of 6.8% ± 0.3% and TIR of 73.9% ± 8.7%, while spending 92.7% of time in AHCL. Users aged older than 15 years (N = 8874) achieved a GMI of 6.8% ± 0.4% and TIR of 76.5% ± 9.4% with 92.3% of time in AHCL. Time spent at less than 70 mg/dl was within the recommended target of less than 4% (3.2% and 2.3%, respectively). Similar outcomes were observed for each group (N = 790 and N = 1642, respectively) in the first month following AHCL initiation, and were sustained over the 6-month observation period.
This real-world analysis shows that more than 75% of users with T1D aged 15 years or younger using the MiniMed 780G system achieved international consensus-recommended glycaemic control, mirroring the achievements of the population aged older than 15 years.
调查使用美敦力780G高级混合闭环（AHCL）系统的15岁及以下和15岁以上1型糖尿病（T1D）患者的实际血糖结果和达成的目标。
汇总2020年8月27日至2021年7月22日美敦力780G系统用户上传的数据，并根据自我报告的年龄（≤15岁和>15岁）对三个队列进行回顾性分析：（a）AHCL启动后，（b）AHCL启动后6个月纵向数据，以及（c）AHCL启动前后。分析内容包括在AHCL模式下以及处于传感器血糖范围内所花费时间的平均百分比、胰岛素输注量，以及达到推荐血糖管理指标（血糖管理指标<7.0%）和目标范围内时间（血糖目标范围70 - 180mg/dl>70%）目标的用户比例。
15岁及以下的用户（N = 3211）血糖管理指标为6.8%±0.3%，目标范围内时间为73.9%±8.7%，在AHCL模式下的时间占92.7%。15岁以上的用户（N = 8874）血糖管理指标为6.8%±0.4%，目标范围内时间为76.5%±9.4%，在AHCL模式下的时间占92.3%。血糖低于70mg/dl的时间在推荐目标的4%以内（分别为3.2%和2.3%）。在AHCL启动后的第一个月，每组（分别为N = 790和N = 1642）都观察到了类似的结果，并且在6个月的观察期内持续存在。
这项实际数据分析表明，使用美敦力780G系统的15岁及以下T1D患者中，超过75%实现了国际共识推荐的血糖控制，与15岁以上人群的成果相当。
Zotero 插件
